Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 3-Part, Randomized, Placebo-controlled, Double-blind, Single Ascending Dose Study to Investigate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-64140284 in Healthy Subjects

Next Previous
X
Search
Trial Profile

A 3-Part, Randomized, Placebo-controlled, Double-blind, Single Ascending Dose Study to Investigate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-64140284 in Healthy Subjects

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 05 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs JNJ-64140284 (Primary)
  • Indications Unspecified
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Janssen Research & Development

    • Most Recent Events

    • 23 Oct 2017 Status changed from suspended to discontinued as SAE has occured. As a measure of precaution, the trial has been stopped.
    • 22 Sep 2017 Status changed from recruiting to suspended as SAE has occured. As a measure of precaution, the dosing of JNJ-64140284 has been suspended for all subjects participating in the trial
    • 16 Jun 2017 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top